Exagen Inc.
clinical laboratory company
XGN Nasdaq
ISIN US30068X1037 SEC CIK 1274737
Follow Exagen
Weekly email: filings, results
Revenue, last quarter
$18.4M
+6.8% vs same quarter last year
Net income
−$6.3M
+10.6% vs same quarter last year
EPS, diluted
−$0.25
+19.4% vs same quarter last year
Operating cash flow
−$2.6M
−187.5% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $66.6M | −$20M |
| FY24 | $55.6M | −$15.1M |
| FY23 | $52.5M | −$23.7M |
| FY22 | $45.6M | −$47.4M |
| FY21 | $48.3M | −$26.9M |
| FY20 | $42M | −$16.7M |
| FY19 | $40.4M | −$12M |
| FY18 | $32.4M | −$8M |
| FY17 | - | - |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 58.3% | −21.1% | −30% |
| FY24 | 59.5% | −24.5% | −27.2% |
| FY23 | 56.1% | −43.5% | −45.1% |
| FY22 | 46.9% | −101.1% | −104% |
| FY21 | 57.4% | −49.8% | −55.6% |
| FY20 | 60.6% | −36.2% | −39.8% |
| FY19 | 53.4% | −23% | −29.8% |
| FY18 | 52.6% | −15% | −24.7% |
| FY17 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$14.3M |
| FY24 | −$13.8M |
| FY23 | −$15.3M |
| FY22 | −$36.5M |
| FY21 | −$22.6M |
| FY20 | −$14.5M |
| FY19 | −$10.1M |
| FY18 | −$9.5M |
| FY17 | - |
- Exagen
- Healthcare median
Show the numbers
| Year | Exagen | Healthcare median |
|---|---|---|
| FY25 | −30% | −30.6% |
| FY24 | −27.2% | −47% |
| FY23 | −45.1% | −58% |
| FY22 | −104% | −80.4% |
| FY21 | −55.6% | −71.8% |
| FY20 | −39.8% | −62.2% |
| FY19 | −29.8% | −46.2% |
| FY18 | −24.7% | −49.6% |
| FY17 | - | −45.9% |